| Literature DB >> 35498793 |
Juan Qiu1,2,3, Jin Ge1, Ling Cao1.
Abstract
Objective: Mycoplasma Pneumoniae (MP) is an important cause of community-acquired pneumonia in children, which can cause serious consequences. There has been some research into predicting Severe Mycoplasma Pneumoniae Pneumonia (SMPP) primarily focused on pre-treatment time by macrolide, pre-hospital course, CRP and LDH et.al. while seldom reporting on concoagulation status. We designed this retrospective study to compare the difference between SMPP and Non-severe MPP (NSMPP) with an attempt to find the risk factors, with a special focus on concoagulation status. Method: We performed a retrospective study of 786 MPP patients who were hospitalized from January 1, 2016 to December 31, 2018, age ranging from 28 days to 18 years old. All patients were divided into SMPP group and NSMPP group. A univariate analysis was conducted between both groups. The factors with statistical differences were included in logistic regression analysis to summarize the predictors of SMPP. Next, the predictive value of each risk factor was calculated from the receiver operating characteristic curve (ROC curve). Patients who had D-dimer records were divided into the elevated D-dimer group (D-dimer > 308ug/L) and the control group (D-dimer ≤ 308ug/L), and the clinical manifestations were compared.Entities:
Keywords: D-dimer; concoagulation status; mycoplasma pneumoniae; pediatrics; risk factor
Year: 2022 PMID: 35498793 PMCID: PMC9039299 DOI: 10.3389/fped.2022.828437
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.569
Clinical characteristic univariate analysis between SMPP and NSMPP.
|
|
|
|
|
|---|---|---|---|
| Age (year) | 6.8 (4) | 6.3 (5) | 0.248 |
| Sex (male/female) | 267/273 | 128/118 | 0.713 |
| Pre-hospital time (d) | 7 (4) | 7 (4) | 0.036 |
| Pre-treatment time (d) | 4.6 ± 2.8 | 4.4 ± 2.8 | 0.301 |
| WBC(×109/L) | 8.23 (2.94) | 7.97 (3.29) | 0.370 |
| N% | 0.58 (0.14) | 0.54 (0.16) | 0.000 |
| PLT (×109/L) | 404 (160) | 360 (141) | 0.000 |
| CRP (mg/L) | 21 (27) | 15 (22) | 0.000 |
| LDH (U/L) | 326 (108.5) | 299 (74.5) | 0.000 |
| D-dimer (ug/L) | 332.5 (460) | 216.5 (139) | 0.000 |
| FIB (g/L) | 3.82 ± 0.66 | 3.81 ± 0.71 | 0.971 |
| APTT (s) | 32.3 (5.4) | 32.7 (4.9) | 0.113 |
| PT (s) | 11.6 (1.1) | 11.5 (1.2) | 0.322 |
| TT (s) | 15.1 (1.6) | 15.1 (1.7) | 0.308 |
Data are presented as means ± SDs or median (quartile).
Binary logistic regression analysis between SMPP and NSMPP.
|
|
|
|
|
|---|---|---|---|
|
| 1 | ||
| 55–67% | 1.428 | 1.015–2.008 | 0.041 |
| > 67% | 3.233 | 2.186–4.784 | 0.00 |
| 1 | |||
| 348–445 × 109 /L | 1.656 | 1.167–2.35 | 0.005 |
| > 445 × 109 /L | 2.589 | 1.779–3.767 | 0.000 |
|
| 1 | ||
| 12–27 mg/L | 1.409 | 1.002–1.982 | 0.049 |
| > 27 mg/L | 3.491 | 2.355–5.174 | 0.000 |
|
| 1 | ||
| 295–354 IU/L | 1.789 | 1.269–2,521 | 0.001 |
| > 354 IU/L | 4.335 | 2.89–6.502 | 0.000 |
|
| 1 | ||
| 219–403 ug/L | 1.562 | 1.114–2.191 | 0.010 |
| >403 ug/L | 7.316 | 4.598–11.642 | 0.000 |
Cut off value between SMPP and NSMPP.
|
|
|
|
|
|
|---|---|---|---|---|
| N% |
|
|
|
|
| PLT | 361 × 109/L | 0.631 | 0.682 | 0.521 |
| CRP | 22 mg/L | 0.638 | 0.488 | 0.739 |
| LDH | 307 U/L | 0.695 | 0.692 | 0.609 |
| D-dimer | 308 ug/L | 0.721 | 0.572 | 0.786 |
Figure 1ROC curve between SMPP and NSMPP.
Complications comparison between elevated D-dimer group and control group.
|
|
|
|
|
|---|---|---|---|
| Pleural effusion | 137 (41.1%) | 33 (21.6%) | 0.001 |
| Atelectasis | 29 (8.7%) | 11 (7.2%) | 0.699 |
| Liver damage | 57 (17.1%) | 3 (2.0%) | 0.001 |
| Myocardial damage | 70 (21.0%) | 11 (7.2%) | 0.003 |
| Rash | 30 (9.0%) | 5 (3.3%) | 0.079 |
| Otitis media | 6 (1.8%) | 0 (0%) | 0.185 |
| Blood electrolytes disturbances | 23 (6.9%) | 1 (0.6%) | 0.05 |
| Anemia | 23 (6.9%) | 5 (3.3%) | 0.281 |
Liver damage is defined as ALT or AST 2 times higher than normal value.
Myocardial damage is defined as CK-MB, CTnT or ECG abnormal.